Daily Ards Research Analysis
Analyzed 3 papers and selected 3 impactful papers.
Summary
Analyzed 3 papers and selected 3 impactful articles.
Selected Articles
1. Unraveling the therapeutic potential of neochlorogenic acid Cu-supramolecular complexes in acute lung injury: Targeting PI3K/NF-κB/iNOS pathway through spatial metabolomics-guided.
In an in vivo ALI model, neochlorogenic acid–copper supramolecular complexes (NA‑Cu) reduced lung edema and lowered IL‑1β, IL‑6, and TNF‑α. Integrated AFADESI‑MSI spatial metabolomics revealed that NA‑Cu reprograms multiple lipid metabolic pathways (sphingolipids, linoleic/α‑linolenic acid, ether lipids, glycerophospholipids, arachidonic acid) and downregulates PI3K/NF‑κB/iNOS signaling, linking metabolic shifts to histological protection.
Impact: Provides a novel preclinical therapeutic candidate (NA‑Cu) with mechanistic insight linking lipid‑metabolism reprogramming to anti‑inflammatory and tissue‑protective effects using spatial metabolomics, advancing translational potential for ALI/ARDS therapies.
Clinical Implications: Preclinical evidence supports NA‑Cu as a candidate for further safety, pharmacokinetics, and dose‑finding studies; if validated, it could inform new anti‑inflammatory, metabolism‑targeted therapies for ALI/ARDS, but clinical translation requires toxicity and efficacy testing in larger animals and early‑phase human trials.
Key Findings
- NA‑Cu reduced lung edema and histological lung injury in an in vivo ALI model.
- NA‑Cu decreased proinflammatory cytokines IL‑1β, IL‑6, and TNF‑α.
- Spatial metabolomics (AFADESI‑MSI) showed NA‑Cu reprogrammed sphingolipid, linoleic/α‑linolenic acid, ether lipid, glycerophospholipid, and arachidonic acid metabolism.
- NA‑Cu effects correlated with suppression of the PI3K/NF‑κB/iNOS signaling axis.
Methodological Strengths
- Integrated spatial metabolomics (AFADESI‑MSI) combined with untargeted metabolomics provides spatially resolved metabolic insight.
- In vivo ALI model with molecular pathway validation linking metabolites to signaling (PI3K/NF‑κB/iNOS).
Limitations
- Preclinical animal study—translational relevance to humans not yet established.
- Sample size and dose‑response/toxicity data are not specified in the provided abstract.
- Potential off‑target effects and long‑term safety were not addressed.
Future Directions: Define NA‑Cu dose–response and toxicology in larger animal models, perform pharmacokinetic profiling, validate the mechanism in human cell/tissue models, and plan early‑phase clinical trials if safety and efficacy are adequate.
BACKGROUND: Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are severe respiratory diseases with high global incidence and mortality. Current therapeutic approaches remain limited, necessitating urgent development of novel treatments. Supramolecular complexes have gained attention in biomedicine due to their unique structural and functional properties.
PURPOSE: This study aimed to evaluate the therapeutic potential of neochlorogenic acid-copper supramolecular complexes (NA-Cu) against ALI/ARDS, building on prior evidence of its anti-inflammatory effects in vitro, and to elucidate its underlying metabolic mechanisms.
STUDY DESIGN: In vivo experimental investigation using an ALI model to assess NA-Cu's effects on lung pathology, inflammatory markers, and metabolic pathways. Mechanistic insights were validated through integrated metabolomics and molecular pathway analysis.
METHODS: The therapeutic efficacy of neochlorogenic acid-copper supramolecular complexes (NA-Cu) was assessed by quantifying its effects on lung edema severity and pro-inflammatory cytokine expression levels (IL-1β, IL-6, TNF-α) in an ALI model. Mechanistic profiling was performed using an integrated analytical approach combining air flow-assisted desorption electrospray ionization mass spectrometry imaging (AFADESI-MSI) with untargeted metabolomics to map spatial metabolic alterations. Subsequently, we screened dysregulated metabolic pathways and signaling cascades, with emphasis on the PI3K/NF-κB/iNOS axis. Validation studies established correlations between NA-Cu-induced metabolic shifts and key therapeutic outcomes, including anti-inflammatory efficacy and histological protection of lung tissue.
RESULTS: This study further found that neochlorogenic acid-copper supramolecular complexes can improve edema in lung tissue by inhibiting the expression of IL-1β, IL-6, and TNF-α. The anti-ALI metabolism mechanism of NA-Cu is revealed through AFADESI-MSI combined with metabolomics. It was found that supramolecular complexes mainly affects sphingolipid metabolism, linoleic acid metabolism, α linolenic acid metabolism, ether lipid metabolism, glycerol phospholipid metabolism, arachidonic acid metabolism and PI3K/NF-κB/iNOS pathway to improve protection of lung tissue.
CONCLUSION: NA-Cu demonstrates robust anti-ALI/ARDS efficacy by synergistically suppressing inflammation and reprogramming lipid metabolism. This study validates the therapeutic promise of supramolecular complexes for ALI treatment and provides novel mechanistic insights into their mode of action.
2. Temporal trends in respiratory parameters and their association with mortality in mechanically ventilated patients with COVID-19-related acute respiratory distress syndrome: the importance of driving pressure.
In this ICU cohort of 585 mechanically ventilated COVID‑19 ARDS patients (median age 70), overall ICU mortality was 57%. Longitudinal analysis of respiratory parameters found that, among mechanics variables, time‑updated driving pressure was the only parameter independently associated with mortality in time‑dependent Cox models.
Impact: Provides longitudinal evidence that monitoring and targeting driving pressure over time (not just at baseline) is important for prognosis in ventilated COVID‑19 ARDS, reinforcing the clinical focus on driving pressure as a modifiable ventilator parameter.
Clinical Implications: Supports protocols emphasizing minimization of driving pressure throughout ventilation (e.g., individualized PEEP and tidal volume strategies) and suggests incorporating time‑updated respiratory mechanics into prognostic models and ventilator management decisions.
Key Findings
- Among multiple longitudinal respiratory parameters, driving pressure was the only mechanics variable independently associated with mortality when analyzed as a time‑updated covariate.
- Dataset included 585 mechanically ventilated COVID‑19 ARDS patients with ICU mortality 57%.
- Serial measurements were taken at days 1, 3, 5, 10, 14, and 21 and analyzed using linear mixed effects and time‑dependent Cox models.
Methodological Strengths
- Relatively large ICU cohort (n=585) with repeated measures at prespecified time points up to day 21.
- Use of linear mixed effects models and time‑dependent Cox regression to account for longitudinal data and time‑varying covariates.
Limitations
- Observational design—potential for residual confounding and inability to prove causality.
- Limited to COVID‑19 ARDS population—generalizability to non‑COVID ARDS may be limited.
- Abstract truncation in provided data prevents assessment of some model covariates and adjustment variables.
Future Directions: Prospective interventional trials targeting driving pressure (e.g., ventilation protocols aimed at minimizing driving pressure) and inclusion of non‑COVID ARDS cohorts to test generalizability; develop prognostic models incorporating time‑updated mechanics.
BACKGROUND: There are limited data on temporal trends of respiratory parameters and their association with mortality in patients with acute respiratory distress syndrome (ARDS). We sought to describe temporal trends of respiratory parameters in mechanically ventilated patients with COVID-19-related ARDS and their relationship with mortality.
METHODS: Patients with COVID-19-related ARDS, undergoing mechanical ventilation, admitted to an intensive care unit (ICU), were included. Data on respiratory parameters were collected on ICU admission (day 1) and on days 3, 5, 10, 14, and 21 thereafter. Linear mixed effects and time-dependent Cox proportional hazards regression analyses were conducted to assess the association between temporal trends of respiratory parameters and mortality.
RESULTS: Data from 585 patients [median (IQR) age 70 [60-77] years, 387 (66%) males] were analyzed. All-cause ICU mortality was 57%. Average values of plateau pressure, respiratory rate, P(A-a)O
CONCLUSION: Temporal trends of respiratory parameters were associated with mortality of mechanically ventilated patients with COVID-19-related ARDS. Among respiratory mechanics variables, driving pressure was the only parameter independently associated with mortality when modeled as a time-updated covariate.
3. Corrigendum to "Ginsenoside Rg1 mitigates sepsis-associated acute respiratory distress syndrome by promoting autophagy through the Prdx1-PTEN/PI3K/AKT pathway" [Phytomedicine Volume 154, May 2026, 158027].
This entry is a corrigendum to a previously published study reporting that ginsenoside Rg1 mitigates sepsis‑associated ARDS by promoting autophagy via the Prdx1‑PTEN/PI3K/AKT pathway. The corrigendum indicates corrections were issued to the original publication (details not provided in the supplied metadata).
Impact: Corrections (corrigenda) maintain scientific integrity; this alerts readers that aspects of the original mechanistic study required amendment and clinicians/researchers should consult the corrected record before applying findings.
Clinical Implications: As a corrigendum, immediate clinical practice change is unlikely; however, anyone referencing or translating the original ginsenoside Rg1 findings into translational steps should review the corrected information to ensure validity.
Key Findings
- A corrigendum has been published for the original paper on ginsenoside Rg1 and sepsis‑associated ARDS.
- The corrigendum indicates modifications to the original publication; the provided metadata does not include the specific corrections.
Methodological Strengths
- Publication of a corrigendum demonstrates editorial and authorial commitment to correcting the scientific record.
Limitations
- Provided metadata lacks detail on what was corrected (methods, results, figures, or other).
- A corrigendum does not provide new experimental data.
Future Directions: Consult the corrected article in Phytomedicine to determine the nature of the amendments; if corrections affect key results, replication or additional validation studies may be warranted.
Corrigendum to "Ginsenoside Rg1 mitigates sepsis-associated acute respiratory distress syndrome by promoting autophagy through the Prdx1-PTEN/PI3K/AKT pathway" [Phytomedicine Volume 154, May 2026, 158027].